Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$27.32 USD

27.32
1,884,690

-0.31 (-1.12%)

Updated Jul 31, 2024 04:00 PM ET

After-Market: $27.30 -0.02 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alkermes (ALKS) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Alkermes (ALKS) reachead $27.92 at the closing of the latest trading day, reflecting a +1.34% change compared to its last close.

Why Is Alkermes (ALKS) Down 1.3% Since Last Earnings Report?

by Zacks Equity Research

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition

by Zacks Equity Research

Alkermes' (ALKS) growth is being driven by the sale of its proprietary products, Vivitrol, Aristada and Lybalvi. However, stiff competition in the target market remains an overhang.

Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '23 View

by Zacks Equity Research

Perrigo (PRGO) reports dismal third-quarter 2023 results. Management lowers guidance for earnings and sales. Stock price drops 5% post the announcement.

CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected

by Zacks Equity Research

CRISPR Therapeutics (CRSP) beats the mark for earnings and misses the same for sales in the third quarter.

Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss

by Zacks Equity Research

Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.

Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.

Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat

by Zacks Equity Research

Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023. Shares fall.

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes (ALKS) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

Alkermes (ALKS) concluded the recent trading session at $27.18, signifying a -1.74% move from its prior day's close.

Alkermes (ALKS) Stock Moves -0.84%: What You Should Know

by Zacks Equity Research

Alkermes (ALKS) closed the most recent trading day at $29.60, moving -0.84% from the previous trading session.

Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Alkermes (ALKS) closed the most recent trading day at $28.85, moving -1.16% from the previous trading session.

Novavax (NVAX) Up 36.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Recently Broke Out Above the 50-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

Here's Why Alkermes (ALKS) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Acadia (ACAD) Down 0.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) Grants Teva License to Market Generic Drug

by Zacks Equity Research

Alkermes (ALKS) grants Teva an exclusive license to market a generic version of Vivitrol in the United States, thereby resolving patent litigation. The stock of the company rises 7%.

Why Is Alkermes (ALKS) Down 9% Since Last Earnings Report?

by Zacks Equity Research

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows

by Zacks Equity Research

Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance.

Bausch Health's (BHC) Q2 Earnings & Sales Beat, '23 View Raised

by Zacks Equity Research

Bausch's (BHC) second-quarter earnings and sales surpass estimates. The company increases its revenue guidance for 2023.

Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology

by Zacks Equity Research

Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.

Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform

by Zacks Equity Research

Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.

Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth

by Zacks Equity Research

Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.

Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y

by Zacks Equity Research

Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliva.